<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266512</url>
  </required_header>
  <id_info>
    <org_study_id>DOCET_L_05158</org_study_id>
    <secondary_id>U1111-1115-3573</secondary_id>
    <nct_id>NCT01266512</nct_id>
  </id_info>
  <brief_title>Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) &amp; Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer</brief_title>
  <acronym>C-CRISP</acronym>
  <official_title>Phase II Study of Concurrent Chemoradiotherapy Using IMRT (With Single Photon Emission Computed Tomography/SPECT-CT to Define Functional Lung Volume and Positron Emission Tomography/PET to Define Gross Tumour Volume/GTV) and Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  Response rate (by contrast CT scan)

      Secondary Objectives:

        -  Progression-free survival (PFS)

        -  Overall survival (OS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for each patient will include an up to 6-week screening phase, 12
      weeks treatment phase (including a resting period of 2 weeks) followed by a long-term
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (by contrast CT scan)</measure>
    <time_frame>12 weeks after completion of adjuvant chemotherapy or within 4 weeks after premature study discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival (PFS)</measure>
    <time_frame>Day 1 of treatment to the date of objective disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Day 1 of treatment to the date of death due to any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (including oesophageal and pulmonary toxicities)</measure>
    <time_frame>Informed consent signature up to 12 weeks after completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>IMRT &amp; docetaxel-cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemo-RT:
Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -
Resting period: 2 weeks -
Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&amp;8 - Cisplatin 35 mg/m² on D1&amp;8 -
Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOCETAXEL</intervention_name>
    <description>Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous</description>
    <arm_group_label>IMRT &amp; docetaxel-cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulated Radiotherapy (IMRT)</intervention_name>
    <description>2 Gy per fraction</description>
    <arm_group_label>IMRT &amp; docetaxel-cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CISPLATIN</intervention_name>
    <description>Pharmaceutical form: solution for infusion Route of administration: intravenous</description>
    <arm_group_label>IMRT &amp; docetaxel-cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Pathologically proven locally advanced, inoperable, confirmed by PET scan (thorax/
             upper abdomen) to be International stage III (2009) NSCLC and without multifocal
             tumours in the lung

          -  Disease volume encompassible within a tolerable Planning Target Volume treated to 66
             Gy

          -  FEV1 (Force Expiratory Volume in 1 Second) &gt;1000 ml

          -  Hemoglobin ≥ 9.0 g/dl

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm3

          -  Platelet count ≥ 100,000/mm3

          -  Total bilirubin ≥ 1.5 times the upper limit of normal

          -  ALT (Alanine Aminotransferase) and AST (Aspartate transaminase) ≤ 2.5 x upper limit of
             normal (≤ 5 x upper limit of normal for patients with liver derangement)

          -  ECOG (Eastern Cooperative Oncology Group) PS 0-1

        Exclusion criteria:

          -  Previous treatment with chest radiotherapy, chemotherapy or molecularly targeted
             agents

          -  Inadequate lung function (Exercise tolerance less than 1 FOS/Fight of stairs, FEV1 &lt; 1
             L/sec, or raised pCO2)

          -  History of hypersensitivity or contraindication to the study drugs or pre-medications
             or products formulated in polysorbate 80

          -  Pregnant or breast-feeding women, or women with child-bearing potential who are not
             following an effective method of contraception and/or who are unwilling or unable to
             be tested for pregnancy (either by serum or urine pregnancy test before study entry

          -  Participation in a clinical trial with any investigational drug used and within 30
             days prior to study entry

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

